|
Market Closed -
Other stock markets
|
After hours 04:55:27 | |||
| 123.53 USD | -0.68% |
|
124.46 | +0.76% |
| 01-12 | Medtronic Reports FDA Clearance for MiniMed Go App | MT |
| 01-09 | Bernstein Adjusts Price Target on Abbott Laboratories to $154 From $150, Maintains Outperform Rating | MT |
| Capitalization | 215B 185B 172B 160B 298B 19,407B 320B 1,981B 780B 9,278B 805B 789B 34,037B | P/E ratio 2025 * |
31.1x | P/E ratio 2026 * | 26.8x |
|---|---|---|---|---|---|
| Enterprise value | 218B 188B 175B 163B 304B 19,742B 326B 2,015B 793B 9,438B 819B 803B 34,624B | EV / Sales 2025 * |
4.89x | EV / Sales 2026 * | 4.47x |
| Free-Float |
86.65% | Yield 2025 * |
1.92% | Yield 2026 * | 2.02% |
Last Transcript: Abbott Laboratories
| 1 day | +0.76% | ||
| 1 week | -2.10% | ||
| Current month | -1.40% | ||
| 1 month | -3.85% | ||
| 3 months | -4.57% | ||
| 6 months | -6.05% | ||
| Current year | -1.40% |
| 1 week | 122.2 |  | 126.6 |
| 1 month | 122.2 | | 129.46 |
| Current year | 122.2 | | 129.46 |
| 1 year | 113.39 | | 141.23 |
| 3 years | 89.67 | | 141.23 |
| 5 years | 89.67 | | 142.6 |
| 10 years | 36 | | 142.6 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Ford
CEO | Chief Executive Officer | 52 | 31/03/2020 |
Philip Boudreau
DFI | Director of Finance/CFO | 53 | 01/09/2023 |
Scott House
CTO | Chief Tech/Sci/R&D Officer | - | 01/03/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Alpern
BRD | Director/Board Member | 75 | 10/10/2008 |
Sally Blount
BRD | Director/Board Member | 64 | 09/12/2011 |
Nancy McKinstry
BRD | Director/Board Member | 67 | 09/12/2011 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +1.50% | 7.18% | 26 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.68% | -2.10% | +11.19% | +8.83% | 215B | |
| +0.26% | +0.31% | +15.93% | +22.84% | 127B | |
| +1.55% | +5.84% | +49.51% | +116.31% | 68.94B | |
| +0.45% | +1.54% | -10.42% | -18.57% | 59.36B | |
| -1.11% | +1.34% | +24.63% | +93.17% | 54.69B | |
| -1.61% | +3.54% | - | - | 35.54B | |
| -0.66% | +1.18% | -13.88% | -36.17% | 27B | |
| +1.52% | +2.91% | +29.81% | +32.78% | 26.33B | |
| +1.34% | -3.72% | +5.77% | -33.34% | 24B | |
| -1.70% | -2.85% | -25.28% | +24.44% | 20.85B | |
| Average | +0.08% | +0.99% | +9.70% | +23.37% | 65.84B | |
| Weighted average by Cap. | +0.35% | +0.47% | +13.79% | +26.33% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 44.68B 38.48B 35.86B 33.36B 62.07B 4,036B 66.58B 412B 162B 1,930B 168B 164B 7,079B | 48.23B 41.55B 38.72B 36.02B 67.01B 4,358B 71.89B 445B 175B 2,083B 181B 177B 7,643B |
| Net income | 6.92B 5.96B 5.56B 5.17B 9.62B 626B 10.32B 63.86B 25.13B 299B 25.96B 25.43B 1,097B | 8.03B 6.91B 6.44B 5.99B 11.15B 725B 11.96B 74.04B 29.13B 347B 30.1B 29.48B 1,272B |
| Net Debt | 3.7B 3.19B 2.97B 2.76B 5.14B 334B 5.52B 34.14B 13.44B 160B 13.88B 13.6B 587B | 686M 591M 550M 512M 953M 61.95B 1.02B 6.32B 2.49B 29.62B 2.57B 2.52B 109B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/01/26 | 123.53 $ | -1.18% | 7,079,477 |
| 14/01/26 | 125.00 $ | +0.56% | 7,187,839 |
| 13/01/26 | 124.30 $ | -0.27% | 5,169,800 |
| 12/01/26 | 124.64 $ | -1.02% | 5,524,324 |
| 09/01/26 | 125.92 $ | -0.21% | 4,317,611 |
Delayed Quote Nyse, January 16, 2026 at 01:02 am
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ABT Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition